This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Allergan Finds a Hole in Valeant & Ackman Partnership

NEW YORK (TheStreet) -- There were no tips on the golf course, no secret meetings on a deal, just a telephone call from Valeant Pharmaceuticals' (VRX - Get Report) CEO to William Ackman of the hedge fund Pershing Square. The call was to seek a partnership between Valeant and Pershing Square to help build a large position in Allergan (AGN - Get Report) stock, win board seats and pressure the company to agree to a deal with Valeant.

Insider trading? Maybe. Against the law? Maybe not. The right way to do business? No way.

This is the first known instance of this tactic. But given the extra scrutiny and lawsuit now being filed it may be the last.

Read More: Johnson & Johnson Can Only Get Better When It Gets Cheaper

In a lawsuit, Botox maker Allergan alleges insider trading by Ackman and rival Valeant. In the civil case filed in California, Allergan states that Pershing Square and Valeant "hatched" an "improper and illicit insider-trading scheme" that allowed Ackman to purchase shares in Allergan ahead of the planned $51 billion buyout.

Pershing Square's 9.7% stake in Allergan, purchased between February and April in the form of call options, and a small $76 million worth of stock, gained $1.2 billion in value the day the buyout plan was announced.

Pershing Square and Valeant have a unique partnership agreement that was set up to skirt insider trading rules. That is the subject of the lawsuit.

Valeant and Ackman appear to have gone wrong, according to Allergan, in the documents they had drawn up by a legion of lawyers, including a former head of the Securities and Exchange Commission. The suitor companies laid out procedures that would be followed should their deal not be accepted by Allergan. In doing so, they possibly broke an SEC rule regarding tender offers.

In the lawsuit, Allergan is arguing Ackman and Valeant violated the S.E.C. rule 10b-5 that makes it illegal to share information before a takeover bid when it is part of a tender offer in which the suitor goes directly to shareholders, bypassing the board. After Allergan rejected the bid, Valeant and Pershing Square began a tender offer on June 18.

Read More: Exclusive: Target Sizing Up Digital Deals

"On April 22, we announced our offer for Allergan. We suspected at the time it would ultimately have to go directly to Allergan shareholders. We were correct." Valeant CEO Pearson stated in a conference call.

When it rains it pours for Bill Ackman. His billion dollar short bet on Herbalife stumbled a week ago when his Herbalife presentation sent shares higher, not lower. Now he's in the news because his Pershing Square fund is being sued for insider trading by Allergan.

Valeant and Pershing are fighting back and attempting to have the lawsuit thrown out.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AGN $240.22 1.21%
VRX $197.84 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs